Which has higher earnings and valuation, PGNY or HNGE?

Progyny has higher revenue and earnings than Hinge Health. Progyny is trading at a lower price-to-earnings ratio than Hinge Health, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Progyny $1.29B 1.63 $58.52M $0.92 29.73 Hinge Health $587.86M 12.20 -$528.26M $1.28 69.42

Is PGNY or HNGE more profitable?

Hinge Health has a net margin of 15.15% compared to Progyny's net margin of 6.00%. Hinge Health's return on equity of 51.60% beat Progyny's return on equity. Company Net Margins Return on Equity Return on Assets Progyny 6.00% 15.98% 10.65% Hinge Health 15.15% 51.60% 14.16%

Does the media refer more to PGNY or HNGE?

In the previous week, Hinge Health had 1 more articles in the media than Progyny. MarketBeat recorded 8 mentions for Hinge Health and 7 mentions for Progyny. Progyny's average media sentiment score of 1.20 beat Hinge Health's score of 0.29 indicating that Progyny is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Progyny 2 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Hinge Health 5 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has higher earnings & valuation, PGNY or CHE?

Chemed has higher revenue and earnings than Progyny. Chemed is trading at a lower price-to-earnings ratio than Progyny, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Progyny $1.29B 1.63 $58.52M $0.92 29.73 Chemed $2.53B 2.66 $265.24M $19.91 25.87

Is PGNY or CHE more profitable?

Chemed has a net margin of 10.60% compared to Progyny's net margin of 6.00%. Chemed's return on equity of 31.77% beat Progyny's return on equity. Company Net Margins Return on Equity Return on Assets Progyny 6.00% 15.98% 10.65% Chemed 10.60% 31.77% 18.90%

Does the media refer more to PGNY or CHE?

In the previous week, Chemed had 3 more articles in the media than Progyny. MarketBeat recorded 10 mentions for Chemed and 7 mentions for Progyny. Progyny's average media sentiment score of 1.20 beat Chemed's score of 1.04 indicating that Progyny is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Progyny 2 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Chemed 6 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has stronger earnings and valuation, PGNY or HIMS?

Hims & Hers Health has higher revenue and earnings than Progyny. Hims & Hers Health is trading at a lower price-to-earnings ratio than Progyny, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Progyny $1.29B 1.63 $58.52M $0.92 29.73 Hims & Hers Health $2.58B 2.48 $128.37M -$0.63 N/A

Does the media favor PGNY or HIMS?

In the previous week, Hims & Hers Health had 26 more articles in the media than Progyny. MarketBeat recorded 33 mentions for Hims & Hers Health and 7 mentions for Progyny. Progyny's average media sentiment score of 1.20 beat Hims & Hers Health's score of 0.18 indicating that Progyny is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Progyny 2 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Hims & Hers Health 3 Very Positive mention(s) 5 Positive mention(s) 23 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has preferable valuation & earnings, PGNY or RDNT?

Progyny has higher earnings, but lower revenue than RadNet. RadNet is trading at a lower price-to-earnings ratio than Progyny, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Progyny $1.29B 1.63 $58.52M $0.92 29.73 RadNet $2.04B 2.91 -$18.65M -$0.27 N/A

Is PGNY or RDNT more profitable?

Progyny has a net margin of 6.00% compared to RadNet's net margin of -0.93%. Progyny's return on equity of 15.98% beat RadNet's return on equity. Company Net Margins Return on Equity Return on Assets Progyny 6.00% 15.98% 10.65% RadNet -0.93% 2.61% 0.91%

Does the media favor PGNY or RDNT?

In the previous week, RadNet had 1 more articles in the media than Progyny. MarketBeat recorded 8 mentions for RadNet and 7 mentions for Progyny. Progyny's average media sentiment score of 1.20 beat RadNet's score of 0.84 indicating that Progyny is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Progyny 2 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive RadNet 2 Very Positive mention(s) 0 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer PGNY or LFST?

In the previous week, LifeStance Health Group had 11 more articles in the media than Progyny. MarketBeat recorded 18 mentions for LifeStance Health Group and 7 mentions for Progyny. Progyny's average media sentiment score of 1.20 beat LifeStance Health Group's score of 0.85 indicating that Progyny is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Progyny 2 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive LifeStance Health Group 8 Very Positive mention(s) 1 Positive mention(s) 7 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Progyny (PGNY) Competitors

$27.35 +0.27 (+1.00%)

Closing price 09/11/2026 04:00 PM Eastern

Extended Trading

$27.36 +0.00 (+0.02%)

As of 09/11/2026 07:30 PM Eastern

Compare

PGNY vs. HNGE, CHE, HIMS, RDNT, and LFST

Should you buy Progyny stock or one of its competitors? Progyny's main competitors and comparable companies include Hinge Health (HNGE), Chemed (CHE), Hims & Hers Health (HIMS), RadNet (RDNT), and LifeStance Health Group (LFST). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "healthcare services" industry.

How does Progyny compare to Hinge Health?

Progyny (NASDAQ:PGNY) and Hinge Health (NYSE:HNGE) are both mid-cap healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their media sentiment, profitability, institutional ownership, valuation, earnings, dividends, analyst recommendations and risk.

Progyny has higher revenue and earnings than Hinge Health. Progyny is trading at a lower price-to-earnings ratio than Hinge Health, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Progyny	$1.29B	1.63	$58.52M	$0.92	29.73
Hinge Health	$587.86M	12.20	-$528.26M	$1.28	69.42

Progyny currently has a consensus price target of $34.36, indicating a potential upside of 25.64%. Hinge Health has a consensus price target of $101.93, indicating a potential upside of 14.71%. Given Progyny's stronger consensus rating and higher possible upside, analysts clearly believe Progyny is more favorable than Hinge Health.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Progyny	0 Sell rating(s)	3 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.85
Hinge Health	1 Sell rating(s)	2 Hold rating(s)	14 Buy rating(s)	1 Strong Buy rating(s)	2.83

In the previous week, Hinge Health had 1 more articles in the media than Progyny. MarketBeat recorded 8 mentions for Hinge Health and 7 mentions for Progyny. Progyny's average media sentiment score of 1.20 beat Hinge Health's score of 0.29 indicating that Progyny is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Progyny	2 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Hinge Health	5 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

94.9% of Progyny shares are held by institutional investors. 9.9% of Progyny shares are held by company insiders. Comparatively, 18.9% of Hinge Health shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Hinge Health has a net margin of 15.15% compared to Progyny's net margin of 6.00%. Hinge Health's return on equity of 51.60% beat Progyny's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Progyny	6.00%	15.98%	10.65%
Hinge Health	15.15%	51.60%	14.16%

Progyny has a beta of 0.99, meaning that its stock price is 1% less volatile than the broader market. Comparatively, Hinge Health has a beta of 1.38, meaning that its stock price is 38% more volatile than the broader market.

Summary

Hinge Health beats Progyny on 10 of the 16 factors compared between the two stocks.

How does Progyny compare to Chemed?

Progyny (NASDAQ:PGNY) and Chemed (NYSE:CHE) are both mid-cap healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their risk, earnings, institutional ownership, profitability, dividends, analyst recommendations, media sentiment and valuation.

Progyny presently has a consensus target price of $34.36, indicating a potential upside of 25.64%. Chemed has a consensus target price of $530.75, indicating a potential upside of 3.02%. Given Progyny's stronger consensus rating and higher possible upside, equities research analysts plainly believe Progyny is more favorable than Chemed.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Progyny	0 Sell rating(s)	3 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.85
Chemed	0 Sell rating(s)	5 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.17

Chemed has a net margin of 10.60% compared to Progyny's net margin of 6.00%. Chemed's return on equity of 31.77% beat Progyny's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Progyny	6.00%	15.98%	10.65%
Chemed	10.60%	31.77%	18.90%

In the previous week, Chemed had 3 more articles in the media than Progyny. MarketBeat recorded 10 mentions for Chemed and 7 mentions for Progyny. Progyny's average media sentiment score of 1.20 beat Chemed's score of 1.04 indicating that Progyny is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Progyny	2 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Chemed	6 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Progyny has a beta of 0.99, indicating that its share price is 1% less volatile than the broader market. Comparatively, Chemed has a beta of 0.51, indicating that its share price is 49% less volatile than the broader market.

Chemed has higher revenue and earnings than Progyny. Chemed is trading at a lower price-to-earnings ratio than Progyny, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Progyny	$1.29B	1.63	$58.52M	$0.92	29.73
Chemed	$2.53B	2.66	$265.24M	$19.91	25.87

94.9% of Progyny shares are owned by institutional investors. Comparatively, 95.9% of Chemed shares are owned by institutional investors. 9.9% of Progyny shares are owned by insiders. Comparatively, 3.3% of Chemed shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Summary

Chemed beats Progyny on 9 of the 17 factors compared between the two stocks.

How does Progyny compare to Hims & Hers Health?

Progyny (NASDAQ:PGNY) and Hims & Hers Health (NYSE:HIMS) are both mid-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, risk, profitability, media sentiment, valuation, analyst recommendations, dividends and institutional ownership.

Progyny has a net margin of 6.00% compared to Hims & Hers Health's net margin of -5.51%. Progyny's return on equity of 15.98% beat Hims & Hers Health's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Progyny	6.00%	15.98%	10.65%
Hims & Hers Health	-5.51%	-6.51%	-1.20%

Progyny presently has a consensus target price of $34.36, indicating a potential upside of 25.64%. Hims & Hers Health has a consensus target price of $32.43, indicating a potential upside of 18.18%. Given Progyny's stronger consensus rating and higher probable upside, research analysts plainly believe Progyny is more favorable than Hims & Hers Health.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Progyny	0 Sell rating(s)	3 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.85
Hims & Hers Health	1 Sell rating(s)	12 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.13

Hims & Hers Health has higher revenue and earnings than Progyny. Hims & Hers Health is trading at a lower price-to-earnings ratio than Progyny, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Progyny	$1.29B	1.63	$58.52M	$0.92	29.73
Hims & Hers Health	$2.58B	2.48	$128.37M	-$0.63	N/A

In the previous week, Hims & Hers Health had 26 more articles in the media than Progyny. MarketBeat recorded 33 mentions for Hims & Hers Health and 7 mentions for Progyny. Progyny's average media sentiment score of 1.20 beat Hims & Hers Health's score of 0.18 indicating that Progyny is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Progyny	2 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Hims & Hers Health	3 Very Positive mention(s)	5 Positive mention(s)	23 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

94.9% of Progyny shares are owned by institutional investors. Comparatively, 63.5% of Hims & Hers Health shares are owned by institutional investors. 9.9% of Progyny shares are owned by company insiders. Comparatively, 11.8% of Hims & Hers Health shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Progyny has a beta of 0.99, meaning that its stock price is 1% less volatile than the broader market. Comparatively, Hims & Hers Health has a beta of 2.42, meaning that its stock price is 142% more volatile than the broader market.

Summary

Progyny beats Hims & Hers Health on 11 of the 17 factors compared between the two stocks.

How does Progyny compare to RadNet?

Progyny (NASDAQ:PGNY) and RadNet (NASDAQ:RDNT) are both mid-cap healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their valuation, profitability, media sentiment, risk, institutional ownership, earnings, dividends and analyst recommendations.

94.9% of Progyny shares are held by institutional investors. Comparatively, 77.9% of RadNet shares are held by institutional investors. 9.9% of Progyny shares are held by company insiders. Comparatively, 5.1% of RadNet shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Progyny has a net margin of 6.00% compared to RadNet's net margin of -0.93%. Progyny's return on equity of 15.98% beat RadNet's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Progyny	6.00%	15.98%	10.65%
RadNet	-0.93%	2.61%	0.91%

In the previous week, RadNet had 1 more articles in the media than Progyny. MarketBeat recorded 8 mentions for RadNet and 7 mentions for Progyny. Progyny's average media sentiment score of 1.20 beat RadNet's score of 0.84 indicating that Progyny is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Progyny	2 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
RadNet	2 Very Positive mention(s)	0 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Progyny has a beta of 0.99, indicating that its stock price is 1% less volatile than the broader market. Comparatively, RadNet has a beta of 1.41, indicating that its stock price is 41% more volatile than the broader market.

Progyny has higher earnings, but lower revenue than RadNet. RadNet is trading at a lower price-to-earnings ratio than Progyny, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Progyny	$1.29B	1.63	$58.52M	$0.92	29.73
RadNet	$2.04B	2.91	-$18.65M	-$0.27	N/A

Progyny presently has a consensus target price of $34.36, suggesting a potential upside of 25.64%. RadNet has a consensus target price of $90.00, suggesting a potential upside of 19.22%. Given Progyny's higher possible upside, equities analysts clearly believe Progyny is more favorable than RadNet.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Progyny	0 Sell rating(s)	3 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.85
RadNet	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	2 Strong Buy rating(s)	2.89

Summary

Progyny beats RadNet on 11 of the 17 factors compared between the two stocks.

How does Progyny compare to LifeStance Health Group?

Progyny (NASDAQ:PGNY) and LifeStance Health Group (NASDAQ:LFST) are both mid-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their risk, analyst recommendations, media sentiment, earnings, profitability, institutional ownership, dividends and valuation.

Progyny has higher earnings, but lower revenue than LifeStance Health Group. Progyny is trading at a lower price-to-earnings ratio than LifeStance Health Group, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Progyny	$1.29B	1.63	$58.52M	$0.92	29.73
LifeStance Health Group	$1.42B	3.48	$9.66M	$0.13	99.77

Progyny has a net margin of 6.00% compared to LifeStance Health Group's net margin of 3.19%. Progyny's return on equity of 15.98% beat LifeStance Health Group's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Progyny	6.00%	15.98%	10.65%
LifeStance Health Group	3.19%	3.39%	2.33%

In the previous week, LifeStance Health Group had 11 more articles in the media than Progyny. MarketBeat recorded 18 mentions for LifeStance Health Group and 7 mentions for Progyny. Progyny's average media sentiment score of 1.20 beat LifeStance Health Group's score of 0.85 indicating that Progyny is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Progyny	2 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
LifeStance Health Group	8 Very Positive mention(s)	1 Positive mention(s)	7 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Progyny has a beta of 0.99, indicating that its share price is 1% less volatile than the broader market. Comparatively, LifeStance Health Group has a beta of 1.22, indicating that its share price is 22% more volatile than the broader market.

Progyny currently has a consensus price target of $34.36, indicating a potential upside of 25.64%. LifeStance Health Group has a consensus price target of $12.88, indicating a potential downside of 0.73%. Given Progyny's stronger consensus rating and higher probable upside, research analysts clearly believe Progyny is more favorable than LifeStance Health Group.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Progyny	0 Sell rating(s)	3 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.85
LifeStance Health Group	0 Sell rating(s)	4 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.73

94.9% of Progyny shares are owned by institutional investors. Comparatively, 85.5% of LifeStance Health Group shares are owned by institutional investors. 9.9% of Progyny shares are owned by insiders. Comparatively, 3.5% of LifeStance Health Group shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Summary

Progyny beats LifeStance Health Group on 11 of the 16 factors compared between the two stocks.

Get Progyny News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding PGNY and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

PGNY vs. The Competition

Export

Metric	Progyny	Healthcare Providers & Services Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$2.08B	$9.87B	$7.16B	$12.72B
Dividend Yield	N/A	2.61%	2.56%	11.16%
P/E Ratio	29.73	33.27	272.98	25.27
Price / Sales	1.63	4.85	606.07	75.26
Price / Cash	36.78	125.76	77.04	51.44
Price / Book	4.57	5.29	10.33	6.20
Net Income	$58.52M	$313.25M	$3.49B	$358.27M
7 Day Performance	5.44%	-1.26%	-3.33%	-2.36%
1 Month Performance	7.59%	-0.98%	-0.40%	-2.77%
1 Year Performance	21.50%	15.13%	19.15%	7.64%

Progyny Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
PGNY Progyny	4.4454 of 5 stars	$27.35 +1.0%	$34.36 +25.6%	+18.0%	$2.08B	$1.29B	29.73	310	Positive News Analyst Forecast
HNGE Hinge Health	3.7528 of 5 stars	$92.20 -0.2%	$100.57 +9.1%	+48.0%	$7.45B	$587.86M	72.03	1,437	Analyst Forecast Insider Trade
CHE Chemed	4.41 of 5 stars	$520.82 +0.2%	$530.75 +1.9%	+12.5%	$6.79B	$2.53B	26.16	15,811	Positive News
HIMS Hims & Hers Health	2.693 of 5 stars	$27.66 -0.2%	$32.50 +17.5%	-47.0%	$6.47B	$2.35B	N/A	2,442	Trending News Analyst Forecast
RDNT RadNet	3.2103 of 5 stars	$73.71 flat	$90.00 +22.1%	+2.4%	$5.80B	$2.04B	N/A	11,264	Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:PGNY) was last updated on 9/12/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Progyny (PGNY) Competitors

PGNY vs. HNGE, CHE, HIMS, RDNT, and LFST

How does Progyny compare to Hinge Health?

Summary

How does Progyny compare to Chemed?

Summary

How does Progyny compare to Hims & Hers Health?

Summary

How does Progyny compare to RadNet?

Summary

How does Progyny compare to LifeStance Health Group?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PGNY vs. The Competition

Progyny Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Progyny (PGNY) Competitors

PGNY vs. HNGE, CHE, HIMS, RDNT, and LFST

How does Progyny compare to Hinge Health?

Which has higher earnings and valuation, PGNY or HNGE?

Do analysts prefer PGNY or HNGE?

Does the media refer more to PGNY or HNGE?

Do institutionals & insiders believe in PGNY or HNGE?

Is PGNY or HNGE more profitable?

Which has more risk & volatility, PGNY or HNGE?

Summary

How does Progyny compare to Chemed?

Do analysts recommend PGNY or CHE?

Is PGNY or CHE more profitable?

Does the media refer more to PGNY or CHE?

Which has more volatility and risk, PGNY or CHE?

Which has higher earnings & valuation, PGNY or CHE?

Do institutionals and insiders believe in PGNY or CHE?

Summary

How does Progyny compare to Hims & Hers Health?

Is PGNY or HIMS more profitable?

Do analysts prefer PGNY or HIMS?

Which has stronger earnings and valuation, PGNY or HIMS?

Does the media favor PGNY or HIMS?

Do institutionals & insiders have more ownership in PGNY or HIMS?

Which has more risk & volatility, PGNY or HIMS?

Summary

How does Progyny compare to RadNet?

Do institutionals and insiders hold more shares of PGNY or RDNT?

Is PGNY or RDNT more profitable?

Does the media favor PGNY or RDNT?

Which has more volatility and risk, PGNY or RDNT?

Which has preferable valuation & earnings, PGNY or RDNT?

Do analysts recommend PGNY or RDNT?

Summary

How does Progyny compare to LifeStance Health Group?

Which has stronger earnings & valuation, PGNY or LFST?

Is PGNY or LFST more profitable?

Does the media prefer PGNY or LFST?

Which has more volatility and risk, PGNY or LFST?

Do analysts recommend PGNY or LFST?

Do institutionals & insiders believe in PGNY or LFST?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PGNY vs. The Competition

Progyny Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools